

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
08 February 2024 (08.02.2024)



(10) International Publication Number
WO 2024/031088 A1

(51) International Patent Classification:

C07D 491/22 (2006.01) A61K 31/553 (2006.01)
C07D 491/14 (2006.01) A61K 31/519 (2006.01)
C07D 498/04 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2023/071743

(22) International Filing Date:

04 August 2023 (04.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/395,649 05 August 2022 (05.08.2022) US

(71) Applicant: KUMQUAT BIOSCIENCES INC. [US/US];
10770 Wateridge Circle, Suite 120, San Diego, California
92121 (US).

(72) Inventors: WU, Baogen; 10770 Wateridge Circle, Suite
120, San Diego, California 92121 (US). LI, Liansheng;
10770 Wateridge Circle, Suite 120, San Diego, California
92121 (US). REN, Pingda; 10770 Wateridge Circle, Suite

120, San Diego, California 92121 (US). LIU, Yi; 10770
Wateridge Circle, Suite 120, San Diego, California 92121
(US). ZHAO, Siling; 10770 Wateridge Circle, Suite 120,
San Diego, California 92121 (US). LI, Xiaoming; 10770
Wateridge Circle, Suite 120, San Diego, California 92121
(US). CHEN, Zhiyong; 10770 Wateridge Circle, Suite 120,
San Diego, California 92121 (US). ZHU, Zhimin; 10770
Wateridge Circle, Suite 120, San Diego, California 92121
(US).

(74) Agent: MALECHA, James; WILSON SONSINI
GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto,
California 94304 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: HETEROCYCLIC COMPOUNDS AND USES THEREOF

FIG. 1

		1		20		40	
K-Ras							
(SEQ ID No. 9)	mte-----	----	yklvvv	gagggv	ksal	tiqlqnhfv	deydp
H-Ras							
(SEQ ID No. 10)	mte-----	----	yklvvv	gagggv	ksal	tiqlqnhfv	deydp
N-Ras							
(SEQ ID No. 11)	mte-----	----	yklvvv	gagggv	ksal	tiqlqnhfv	deydp
RalA							
(SEQ ID No. 12)	maankpkqgn	slalhkvimv	gagggv	ksal	tiqfmydefv	edyep	tkads
RalB							
(SEQ ID No. 13)	maankskqqs	slalhkvimv	gagggv	ksal	tiqfmydefv	edyep	tkads
		60		80		100	
K-Ras	tclldildta	gqeeysamrd	qymrtgegfl	cvfainntks	fedihhyreq	ikrvykdsedd-	108
H-Ras	tclldildta	gqeeysamrd	qymrtgegfl	cvfainntks	fedihhyreq	ikrvykdsedd-	108
N-Ras	tclldildta	gqeeysamrd	qymrtgegfl	cvfainntks	fedihhyreq	ikrvykdsedd-	108
RalA	evqidildta	ggedyaaird	nyfrsgegfl	cvfsitemes	faatadfreq	ilrvk-eden	119
RalB	evqidildta	ggedyaaird	nyfrsgegfl	lvfsitehes	ftataefreq	ilrvkaeedk	120

(57) Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of certain oncogenic proteins.

[Continued on next page]

WO 2024/031088 A1

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*